BioCardia, Inc. (BCDA)

Market Cap	5.35M
Revenue (ttm)	468,000
Net Income (ttm)	-10.34M
Shares Out	1.82M
EPS (ttm)	-7.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,300
Open	2.880
Previous Close	2.990
Day's Range	2.880 - 3.125
52-Week Range	2.620 - 43.200
Beta	1.41
Analysts	Strong Buy
Price Target	60.00 (+1,940.82%)
Earnings Date	Aug 7, 2024

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded b...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Peter A. Altman Ph.D.
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCDA

Financial Performance

In 2023, BioCardia's revenue was $477,000, a decrease of -64.72% compared to the previous year's $1.35 million. Losses were -$11.57 million, -2.82% less than in 2022.

Analyst Forecast

According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price forecast is $60.0.

Price Target

$60.0

(1,940.82% upside)

Analyst Consensus: Strong Buy